Abbott R&D increased by 4.4% to $767.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $716.00M to $767.00M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 1.8% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $654.00M | $672.00M | $762.00M | $697.00M | $684.00M | $782.00M | $725.00M | $654.00M | $715.00M | $672.00M | $700.00M | $684.00M | $698.00M | $713.00M | $749.00M | $716.00M | $725.00M | $766.00M | $735.00M | $767.00M |
| QoQ Change | — | +2.8% | +13.4% | -8.5% | -1.9% | +14.3% | -7.3% | -9.8% | +9.3% | -6.0% | +4.2% | -2.3% | +2.0% | +2.1% | +5.0% | -4.4% | +1.3% | +5.7% | -4.0% | +4.4% |
| YoY Change | — | — | — | — | +4.6% | +16.4% | -4.9% | -6.2% | +4.5% | -14.1% | -3.4% | +4.6% | -2.4% | +6.1% | +7.0% | +4.7% | +3.9% | +7.4% | -1.9% | +7.1% |
Range$654.00M – $782.00M
CAGR+3.4%
Avg YoY Growth+2.1%
Median YoY Growth+4.6%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Medical Devices | $401.00M | $430.00M | $462.00M | $460.00M | $444.00M |
| Diagnostic Products | $151.00M | $154.00M | $150.00M | $147.00M | $155.00M |
| Nutritional Products | $52.00M | $54.00M | $55.00M | $52.00M | $54.00M |
| Established Pharmaceuticals | $42.00M | $43.00M | $42.00M | $49.00M | $41.00M |
| Total | $716.00M | $725.00M | $766.00M | $735.00M | $767.00M |
R&D at Other Companies
Frequently Asked Questions
- What is Abbott's r&d?
- Abbott (ABT) reported r&d of $767.00M in Q1 2026.
- How has Abbott's r&d changed year-over-year?
- Abbott's r&d increased by 7.1% year-over-year, from $716.00M to $767.00M.
- What is the long-term trend for Abbott's r&d?
- Over 4 years (2021 to 2025), Abbott's r&d has grown at a 1.8% compound annual growth rate (CAGR), from $2.74B to $2.94B.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.